Furthermore, our study comprehensively addressed multiple pathological features of NASH beyond impaired insulin signaling, such as inflammation and metabolic dysregulation, offering a broader understanding of GP’s therapeutic potential in liver disease. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.